BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 19933832)

  • 1. Plasmodium falciparum merozoite surface protein 1 (MSP-1)-MSP-3 chimeric protein: immunogenicity determined with human-compatible adjuvants and induction of protective immune response.
    Mazumdar S; Mukherjee P; Yazdani SS; Jain SK; Mohmmed A; Chauhan VS
    Infect Immun; 2010 Feb; 78(2):872-83. PubMed ID: 19933832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Production and preclinical evaluation of Plasmodium falciparum MSP-119 and MSP-311 chimeric protein, PfMSP-Fu24.
    Gupta PK; Mukherjee P; Dhawan S; Pandey AK; Mazumdar S; Gaur D; Jain SK; Chauhan VS
    Clin Vaccine Immunol; 2014 Jun; 21(6):886-97. PubMed ID: 24789797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
    Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
    Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and protective efficacy of Escherichia coli expressed Plasmodium falciparum merozoite surface protein-1(42) using human compatible adjuvants.
    Sachdeva S; Mohmmed A; Dasaradhi PV; Crabb BS; Katyal A; Malhotra P; Chauhan VS
    Vaccine; 2006 Mar; 24(12):2007-16. PubMed ID: 16377036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antigenicity of a Bacterially Expressed Triple Chimeric Antigen of Plasmodium falciparum AARP, MSP-311 and MSP-119: PfAMSP-Fu35.
    Kalra A; Edula JR; Gupta PK; Pandey AK; Chauhan VS
    PLoS One; 2016; 11(10):e0165720. PubMed ID: 27798691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphism and epitope sharing between the alleles of merozoite surface protein-1 of Plasmodium falciparum among Indian isolates.
    Mamillapalli A; Sunil S; Diwan SS; Sharma SK; Tyagi PK; Adak T; Joshi H; Malhotra P
    Malar J; 2007 Jul; 6():95. PubMed ID: 17659072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis of the profiles of IgG subclass-specific responses to Plasmodium falciparum apical membrane antigen-1 and merozoite surface protein-1 in naturally exposed individuals living in malaria hypoendemic settings, Iran.
    Rouhani M; Zakeri S; Mehrizi AA; Djadid ND
    Malar J; 2015 Feb; 14():58. PubMed ID: 25652589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune responses elicited by co-immunization of Plasmodium vivax and P. falciparum MSP-1 using prime-boost immunization strategies.
    Mehrizi AA; Zakeri S; Rafati S; Salmanian AH; Djadid ND
    Parasite Immunol; 2011 Nov; 33(11):594-608. PubMed ID: 21883290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poly(I:C) adjuvant strongly enhances parasite-inhibitory antibodies and Th1 response against Plasmodium falciparum merozoite surface protein-1 (42-kDa fragment) in BALB/c mice.
    Mehrizi AA; Rezvani N; Zakeri S; Gholami A; Babaeekhou L
    Med Microbiol Immunol; 2018 Apr; 207(2):151-166. PubMed ID: 29397427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced protection against malaria by a chimeric merozoite surface protein vaccine.
    Shi Q; Lynch MM; Romero M; Burns JM
    Infect Immun; 2007 Mar; 75(3):1349-58. PubMed ID: 17158895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and in vitro protective efficacy of recombinant Mycobacterium bovis bacille Calmette Guerin (rBCG) expressing the 19 kDa merozoite surface protein-1 (MSP-1(19)) antigen of Plasmodium falciparum.
    Nurul AA; Norazmi MN
    Parasitol Res; 2011 Apr; 108(4):887-97. PubMed ID: 21057812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies against multiple merozoite surface antigens of the human malaria parasite Plasmodium falciparum inhibit parasite maturation and red blood cell invasion.
    Woehlbier U; Epp C; Hackett F; Blackman MJ; Bujard H
    Malar J; 2010 Mar; 9():77. PubMed ID: 20298576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I Clinical Trial of a Recombinant Blood Stage Vaccine Candidate for Plasmodium falciparum Malaria Based on MSP1 and EBA175.
    Chitnis CE; Mukherjee P; Mehta S; Yazdani SS; Dhawan S; Shakri AR; Bhardwaj R; Gupta PK; Hans D; Mazumdar S; Singh B; Kumar S; Pandey G; Parulekar V; Imbault N; Shivyogi P; Godbole G; Mohan K; Leroy O; Singh K; Chauhan VS
    PLoS One; 2015; 10(4):e0117820. PubMed ID: 25927360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antibody response to Plasmodium falciparum Merozoite Surface Protein 4: comparative assessment of specificity and growth inhibitory antibody activity to infection-acquired and immunization-induced epitopes.
    de Silva HD; Saleh S; Kovacevic S; Wang L; Black CG; Plebanski M; Coppel RL
    Malar J; 2011 Sep; 10():266. PubMed ID: 21920045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Merozoite Surface Protein 1 from Plasmodium falciparum Is a Major Target of Opsonizing Antibodies in Individuals with Acquired Immunity against Malaria.
    Jäschke A; Coulibaly B; Remarque EJ; Bujard H; Epp C
    Clin Vaccine Immunol; 2017 Nov; 24(11):. PubMed ID: 28877929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of an immunologically reactive merozoite surface protein (MSP-1(42)) in E. coli.
    Leung WH; Meng ZQ; Hui G; Ho WK
    Biochim Biophys Acta; 2004 Nov; 1675(1-3):62-70. PubMed ID: 15535968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A malaria vaccine based on the polymorphic block 2 region of MSP-1 that elicits a broad serotype-spanning immune response.
    Cowan GJ; Creasey AM; Dhanasarnsombut K; Thomas AW; Remarque EJ; Cavanagh DR
    PLoS One; 2011; 6(10):e26616. PubMed ID: 22073118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies that inhibit malaria merozoite surface protein-1 processing and erythrocyte invasion are blocked by naturally acquired human antibodies.
    Guevara Patiño JA; Holder AA; McBride JS; Blackman MJ
    J Exp Med; 1997 Nov; 186(10):1689-99. PubMed ID: 9362529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative testing of six antigen-based malaria vaccine candidates directed toward merozoite-stage Plasmodium falciparum.
    Arnot DE; Cavanagh DR; Remarque EJ; Creasey AM; Sowa MP; Morgan WD; Holder AA; Longacre S; Thomas AW
    Clin Vaccine Immunol; 2008 Sep; 15(9):1345-55. PubMed ID: 18550731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody responses to a novel Plasmodium falciparum merozoite surface protein vaccine correlate with protection against experimental malaria infection in Aotus monkeys.
    Cavanagh DR; Kocken CH; White JH; Cowan GJ; Samuel K; Dubbeld MA; Voorberg-van der Wel A; Thomas AW; McBride JS; Arnot DE
    PLoS One; 2014; 9(1):e83704. PubMed ID: 24421900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.